ONWARD Medical to Announce First-Half 2026 Results on September 9, 2026
ONWARD Medical (ONWRY) will release its first-half 2026 financial results and provide a comprehensive business update via webcast on September 9, 2026.
Rhea-AI Summary
ONWARD Medical (ONWRY) will release its first-half 2026 financial results and provide a comprehensive business update via webcast on September 9, 2026. CEO Dave Marver will host the event starting at 2:00 p.m. CEST / 8:00 a.m. EDT, with registration required to join the live session.
A replay of the webcast and supporting materials will be available on the company’s investor relations site. ONWARD Medical develops its proprietary ARC Therapy and offers the ARC-EX external system, cleared for sale in the US and Europe, while also advancing investigational implantable and BCI-enabled systems for spinal cord injury and movement disabilities.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EINDHOVEN, the Netherlands, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announced that it will release its first-half 2026 financial results and host a webcast with a comprehensive business update on September 9, 2026.
The webcast, presented by CEO Dave Marver, will begin at 2:00 p.m. CEST / 8:00 a.m. EDT. To join, please register using this link. A replay of the webcast and supporting materials will be available at ir.onwd.com.
About ONWARD Medical
ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities. Building on decades of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed its proprietary ARC Therapy. It has subsequently been awarded 10 Breakthrough Device Designations from the FDA. The Company’s ARC-EX® System is cleared for commercial sale in the US and Europe. The Company is also developing an investigational implantable system called ARC-IM®, designed to address several unmet needs including blood pressure instability after spinal cord injury. It can also be paired with a brain-computer interface (BCI) and artificial intelligence (AI) to restore thought-driven movement.
Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD), and its US ADRs can be traded on OTCQX (ticker: ONWRY).
To learn more about ONWARD Medical’s commitment to partnering with the spinal cord injury community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit ONWD.com.
To be kept informed about the Company’s technologies, research studies, and the availability of therapies in your area, please complete this webform.
For Media Inquiries:
Sébastien Cros, VP Communications
media@onwd.com
For Investor Inquiries:
investors@onwd.com
Disclaimer
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited.
Investigational Products: ARC-IM and ARC-BCI are investigational and not available for commercial use. ARC-IM is limited by United States law to investigational use.
FAQ
When will ONWARD Medical (ONWRY) report its first-half 2026 financial results?
ONWARD Medical will release its first-half 2026 financial results on September 9, 2026. The announcement will be accompanied by a webcast that also includes a comprehensive business update presented by the company’s CEO.
What time is the ONWARD Medical (ONWRY) first-half 2026 results webcast and who is presenting?
The webcast for ONWARD Medical’s first-half 2026 results will begin at 2:00 p.m. CEST / 8:00 a.m. EDT on September 9, 2026. It will be presented by CEO Dave Marver and will include a detailed business update.
How can investors access the ONWARD Medical (ONWRY) first-half 2026 earnings webcast and replay?
To join the live webcast, participants must register via the provided link. After the event, a replay of the webcast and supporting materials will be available on ONWARD Medical’s investor relations website at ir.onwd.com.
What does ONWARD Medical (ONWRY) do in the field of spinal cord injury?
ONWARD Medical is a neurotechnology company developing therapies to restore movement, function, and independence in people with spinal cord injuries and other movement disabilities. Its proprietary ARC Therapy is delivered through systems such as the ARC-EX external device and investigational implantable technologies.
Which ONWARD Medical products are commercially available and which are investigational?
ONWARD Medical’s ARC-EX System is cleared for commercial sale in the US and Europe. The ARC-IM implantable system and ARC-BCI brain-computer interface are described as investigational and are not available for commercial use, with ARC-IM limited in the US to investigational use.